Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease

被引：1
|
作者：
De la Garza-Salazar, Fernando
Colunga-Pedraza, Perla Rocio
Coronado-Alejandro, Edgar Ulises
Gutierrez-Aguirre, Cesar Homero
Cantu-Rodriguez, Olga Graciela
Gomez-Almaguer, David [1 ,2 ]
机构：
[1] Univ Autonoma Nuevo Leon, Fac Med, Monterrey, Mexico
[2] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Hematol Serv, Internal Med Dept, Monterrey, Mexico
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期
关键词：
chronic graft versus host disease; CYP; ibrutinib; itraconazole; low dose;
D O I：
10.1111/bjh.18712
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：573 / 576
页数：4
相关论文
共 50 条
  • [41] Novel strategies for steroid-refractory acute graft-versus-host disease
    Bolaños-Meade, J
    Vogelsang, GB
    CURRENT OPINION IN HEMATOLOGY, 2005, 12 (01) : 40 - 44
  • [42] MICA is not a direct humoral allogeneic target in steroid-refractory chronic graft-versus-host disease
    Whittle, R.
    Goodwin, J.
    Smillie, D.
    Harmer, A.
    Taylor, P.
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2010, 37 (05) : 430 - 430
  • [43] Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease
    Nikiforow, Sarah
    Kim, Haesook T.
    Bindra, Bhavjot
    McDonough, Sean
    Glotzbecker, Brett
    Armand, Philippe
    Koreth, John
    Ho, Vincent T.
    Alyea, Edwin P., III
    Blazar, Bruce R.
    Ritz, Jerome
    Soiffer, Robert J.
    Antin, Joseph H.
    Cutler, Corey S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (05) : 804 - 811
  • [44] Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
    Wang, Dong
    Liu, Yin
    Lai, Xiaoxuan
    Chen, Jia
    Cheng, Qiao
    Ma, Xiao
    Lin, Zhihong
    Wu, Depei
    Xu, Yang
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease
    Nikiforow, Sarah
    Kim, Haesook T.
    Bindra, Bhavjot
    McDonough, Sean
    Glotzbecker, Brett
    Armand, Philippe
    Koreth, John
    Ho, Vincent T.
    Alyea, Edwin P., III
    Ritz, Jerome
    Soiffer, Robert J.
    Antin, Joseph H.
    Cutler, Corey
    BLOOD, 2012, 120 (21)
  • [46] Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study
    Dal Sinan, Mehmet
    Batgi, Hikmettullah
    Erkurt, Mehmet Ali
    Hindilerden, Ipek Yonal
    Kuku, Irfan
    Kurtoglu, Erdal
    Kaya, Emin
    Besisik, Sevgi Kalayoglu
    Berber, Ilhami
    Nalcaci, Meliha
    Ulas, Turgay
    Altuntas, Fevzi
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (05)
  • [47] Treatment of steroid-refractory acute and chronic graft-versus-host disease with ruxolitinib in adults and children
    Moiseev, Ivan
    Morozova, Elena
    Barabanshikova, Maria
    Kozlov, Andrey
    Rudakova, Tatyana
    Klimova, Olesya
    Tcvetkov, Nikolai
    Pirogova, Olga
    Borzenkova, Evgeniya
    Kozhokar, Polina
    Ekushev, Kirill
    Paina, Olesya
    Bykova, Tatyana
    Darskaya, Elena
    Bondarenko, Sergey
    Zubarovskaya, Ludmila
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2018, 53 : 461 - 462
  • [48] Ruxolitinib in chronic steroid-refractory graft-versus-host-disease.
    Kovalenko, Iuliia
    Saleem, Tabinda
    Laek, Babray
    Ali, Rimsha
    Mirza, Taaha Muddassir
    Chattaraj, Asmi
    Wahab, Ahsan
    Din, Asma Tamez Ud
    Qurashi, Hafiz
    Golubykh, Konstantin
    Malik, Maidah
    Khan, Rafiullah
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Ruxolitinib as a treatment option for steroid-refractory severe graft-versus-host disease - case report
    Paul, S.
    Wass, M.
    Mueller-Tidow, C.
    Mueller, L. P.
    Oncology Research and Treatment, 2015, 38 : 53 - 53
  • [50] Strategy on the Treatment of Steroid-Refractory Severe acute Graft-versus-Host Disease
    Yamin, T.
    Yi, L.
    Kaili, D.
    He, H.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S393 - S394
12345